On May 18, 2020, Moderna announced encouraging preliminary results from the National Institute for Allergy and Infectious Diseases ("NIAID")'s Phase 1 trial of the Company's Covid-19 vaccine candidate, mRNA-1273. Following the announcement, Moderna's stock price spiked nearly 20%.

However, the next day, the health news website STAT published an article casting doubt on the prudence of the Company's optimism and highlighting the lack of key data in Moderna's statements. Specifically, the article stated that vaccine experts had concluded that "there's really no way to know how impressive - or not - the vaccine may be."

Following the article, Moderna's stock price plummeted, closing at $57.71 per share on May 27, 2020, even lower than Moderna was trading prior to the announcement of positive preliminary results. Further, related news articles have leveled accusations of insider trading against Moderna executives.

To obtain additional information, go to:

https://www.zlk.com/pslra-1/moderna-inc-information-request-form

or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut and Washington D.C. The firm's attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/57730